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S UMMA R Y
Crucial to finding and treating the 4 million tuberculosis
(TB) patients currently missed by national TB pro-
grammes, TB stigma is receiving well-deserved and long-
delayed attention at the global level. However, the
ability to measure and evaluate the success of TB stigma-
reduction efforts is limited by the need for additional
tools. At a 2016 TB stigma-measurement meeting held
in The Hague, The Netherlands, stigma experts dis-
cussed and proposed a research agenda around four
themes: 1) drivers: what are the main drivers and
domains of TB stigma(s)?; 2) consequences: how
consequential are TB stigmas and how are negative
impacts most felt?; 3) burden: what is the global
prevalence and distribution of TB stigma(s) and what
explains any variation? 4): intervention: what can be
done to reduce the extent and impact of TB stigma(s)?
Each theme was further subdivided into research topics
to be addressed to move the agenda forward. These
include greater clarity on what causes TB stigmas to
emerge and thrive, the difficulty of measuring the
complexity of stigma, and the improbability of a
universal stigma ‘cure’. Nevertheless, these challenges
should not hinder investments in the measurement and
reduction of TB stigma. We believe it is time to focus on
how, and not whether, the global community should
measure and reduce TB stigma.
K E Y WO R D S : discrimination; human rights; social
justice; respect; equity
TUBERCULOSIS (TB) STIGMA is beginning to
receive some well-deserved attention at the global
level.1 ‘Zero suffering’ is one of the three goals of the
World Health Organization’s End TB Strategy, and
reference to stigma is common in key implementation
documents.2 The Global Fund has declared TB stigma
to be among the most commonly identified barriers to
fighting the epidemic,3 and United Nations agencies
have called for an end to discrimination in health
care.1
Many experts believe that it will be difficult to find
the estimated 4 million missing TB cases without
addressing TB stigma.1,4 Experts also believe that the
full potential of new drugs and regimens for
multidrug-resistant TB (MDR-TB), paediatric TB
and latent tuberculous infection (LTBI) cannot be
realised without addressing TB stigma. Increasingly,
countries using Global Fund support are attempting
to reduce TB stigma and discrimination across and
within elements of their TB programmes. However,
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the capacity to measure and evaluate the success of
these interventions needs to be fostered.5–8
To begin to address this gap, an expert meeting
took place in May 2016 to discuss the measurement
issues surrounding TB stigma. This article outlines a
research agenda for improving the measurement of
and action on TB stigma, and is a product of that
meeting. The ultimate aim of this research agenda is
catalytic. We want researchers, TB activists, and
programme managers to measure TB stigma appro-
priately and enable them to design, implement and
evaluate interventions to reduce the impact TB stigma
has on patients, families, health workers, communi-
ties and the epidemic itself. While there are many
ways to define stigma, we draw on Weiss et al.’s
definition: ‘a social process, experienced or antici-
pated, characterised by exclusion, rejection, blame or
devaluation, that results from experience, perception,
or reasonable anticipation of an adverse social
judgment about a person or group’.9
METHOD
Expert meeting
At a 3-day TB stigma measurement meeting hosted by
the KNCV Tuberculosis Foundation in The Hague,
The Netherlands, in 2016, stigma experts gathered to
discuss the status of TB stigma measurement science
and define which steps might be taken to improve
tracking of TB stigma dynamics. Using free mapping,
small group discussions and plenary debate, the
group distilled the priorities and the proposed study
designs or methodologies for the main research
priorities summarised under four themes: Theme 1
(drivers): what are the main drivers and domains of
TB stigma(s)? Theme 2 (consequences): how conse-
quential are TB stigmas and how are TB stigma(s)
impacts felt? Theme 3 (burden): what is the global
prevalence and distribution of TB stigma(s) and what
explains any variation? Theme 4 (intervention): what
can be done to reduce the extent and impact of TB
stigma(s)?
General principles
In advance of the meeting, we leveraged information
from studies already conducted on TB stigma, and
commissioned four new studies, including two
systematic reviews of published stigma scales and
interventions.10–13 Link et al., Weiss et al., Pescoso-
lido et al. and others have described the extent of how
TB stigma can be observed, felt and resisted at
different levels of society.9,14–19 TB stigma can also be
present at the level of societal discourse where
cultural and social determinants may be more or less
important.14,20 We also learned from research on
stigmas other than for TB, with the caveat that not
everything will translate readily. Finally, we built on
the work that has outlined the typologies of
stigma,20,21 which are produced in different ways.9
‘Anticipated stigma’ (perceived stigma) is the
worry that one will be devalued or tainted if one is
found to have a TB diagnosis. While these fears may
not actually materialise, anticipated stigma may
interfere with care seeking and treatment adherence.
‘Secondary stigma’ refers to the taint that care givers,
friends, family members, health workers or those in
TB-associated industries (e.g., miners), may experi-
ence because of their link to TB or TB patients.22,23
‘Internalised stigma’ or ‘self-stigma’ captures the idea
that individuals may come to endorse negative
attitudes about themselves, and therefore behave or
think according to these negative messages.24 ‘Enact-
ed stigma’ refers to behaviours, including micro-
aggression, discrimination, rejection, isolation and
denial of rights. It is useful to distinguish between
enacted stigma and experienced stigma as two sides of
the same coin, seen from the perspective of either the
stigmatiser (enacted) or the stigmatised (experi-
enced). Finally, ‘structural stigma’ describes laws,
policies and institutional architecture that may be
prejudicial or denigrating.
RESULTS
We developed a matrix of types of stigma and the
populations that may produce them or be affected by
stigma. We separated types of stigma (anticipated,
courtesy, internalised/self, enacted or experienced and
structural) from the drivers and consequences of
stigma. The drivers of stigma(s) are factors that
facilitate the stigmatisation process (e.g., infectious-
ness of TB, power differentials, ignorance, discrimi-
natory laws). The consequences of stigma (e.g., non-
disclosure, poor adherence, depression, stress, poor
health-seeking behaviour, self-isolation, reduced
quality of life, social distancing, forced isolation)
must also be captured and measured, and need to be
separated from the drivers or causes of stigma.
Based on this approach, we considered a matrix of
types of TB stigma and the populations that may
produce them or be affected by stigma. Table 1 links
the different forms of stigma and the specific groups
(dyads) involved in producing them. Amore complete
picture would be three-dimensional, including the
social and political spaces in which TB stigma(s) are
enacted (Table 1).
Research agenda for the measurement of TB stigma
For each of the four key research thematic areas, we
defined the main research questions, foundation
studies, levels or subpopulations and study designs
or methodologies most fitting to address these
questions. One conclusion reached was that much
of the existing TB stigma research has focused on TB
patients (individuals who made it into a health
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system). There may thus be much we still do not
know about the prevalence, degree and impact of TB
stigma among missing cases: those who fail to make it
into the facilities. We therefore propose that future
work should cast a wider net to include a broader set
of actors, including the general public, community
leaders, media, policy makers, health care workers
and community health workers (HCWs/CHWs), and
explore protective as well as risk factors.
Theme I: What are the main drivers and domains of TB
stigma(s)?
To address this theme, one must articulate the
complex constructs underlying stigma. So far, in-
depth qualitative work around why and how stigma
emerges and which facilitators sustain it remains
scarce. As one reviewer notes, ‘most authors on TB
stigma seem to point to the fundamental cause of the
stigma being the perceived contagiousness of
TB’.34,35 In contrast, in their study of TB stigma in
five health systems in Nicaragua, Macq et al. found
that the ‘determinants of stigma . . . were the content
and channels of information, and issues of domina-
tion and power.’36
A persistent quandary around disentangling TB
stigma from other stigmatised identities hinders study
of the drivers of TB stigma. In other words, it remains
unclear how and when the roots of TB stigma differ
from other stigmatised identities such as having
human immunodeficiency virus (HIV) infection,
being poor, homeless, an immigrant, or being
dependent on drugs or alcohol.37,38 Some argue that
TB stigma is hard to distinguish from xenophobia,
elitism and racism.9,39 Other researchers suggest it is
so bound up with HIV stigma that trying to tease
them apart may be a fool’s errand.13,40–42
Specific drivers may depend on the type of stigma,
setting, population and type of TB. Structural stigmas
can be driven by power differentials, whereas
anticipated stigma thrives on misinformation. Drivers
may also differ by epidemic characteristics (low- or
high-burden settings) or by the populations impacted
(age, sex and class).9,14,43,44 Stigma toward people
with MDR-TB and extensively drug-resistant TB
(XDR-TB) and those with LTBI is likely fostered and
sustained by distinct sets of underlying factors. The
drivers of MDR-TB stigma may be weighted distinct-
ly from drug-susceptible TB stigma in three ways.
First, one of the classical facets of any stigma
construct is the social designation of ‘dangerousness’.
If a person has MDR- or XDR-TB, doubts about
curability may fuel the social construction of MDR-
TB patients as embodying a mortal risk to others. The
second classical facet of stigma is the conscious
attachment of blame for one’s mark or condition.19,45
In the case of MDR-TB, there may be treatment-
adherence behaviours that may at times contribute to
the development of drug resistance, creating rhetor-
ical opportunities to blame individuals for their
disease. Third, MDR-TB patients are more likely to
experience perception-altering side effects as a
consequence of their treatment and catastrophic costs
due to the length of their treatment, both of which
can heighten their vulnerability to stigma.46 Hearing
loss, psychological side effects and impoverishment
can reinforce the social construction of MDR-TB
patients as ‘deviant’, ‘unpredictable’ and ‘other’.
Given the complexity of TB stigma, we believe that
qualitative research before, during or after quantita-
tive research is essential to ensure that the nuance and
meanings are not lost in the numbers (Table 2).
Theme II: How consequential are TB stigmas? How are
TB stigma(s) impacts felt?
Understanding when and how TB stigma is problem-
atic is vital. Figure 1 illustrates the potential impacts
of stigma along a person’s trajectory of TB infection,
disease and recovery. Assessing stigma at the individ-
ual behavioural level is crucial to determine how TB
stigma hampers case finding and recovery from TB or
MDR-TB. A recent systematic review of TB scales
concluded that researchers should optimise existing
TB stigma scales and develop new ones to better
capture specific micro-, meso- and macro-level
constructs (Figure 1).53
We recognise that TB stigma interacts on complex
levels with psychological, social and political fac-
tors.41,43,54 The impact of stigma is therefore not
unidirectional and not always negative. For example,
stigma can make some patients more adherent29,55
and some less adherent.56 Furthermore, stigma’s
consequences may vary for different groups, individ-
uals, and settings.15,42,44,57,58 Intersectional ap-
Table 1 Matrix of illustrative scales used in referenced studies, by type of TB stigma and affected population
Anticipated
stigma
Courtesy
stigma
Internalised/
self-stigma
Enacted or experienced
stigma (discrimination)
Structural stigma
(policies, laws, architecture,
human rights)
General public 25–27 13
Subgroups at higher risk of TB 28
TB patients 15,29–31 32
Health care workers 33 33
Policy makers STP legal environment assessment
TB¼ tuberculosis; STP¼ STOP TB Partnership.
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proaches that address multiple forms of exclusion are
essential.13
Different types of stigma (anticipated/felt, courtesy,
internalised/self and enacted) impact at distinct levels
(individual, family, community). Building on existing
work, we identified the main research questions and
gaps in our understanding of the impact of TB
stigma(s) (see Table 3).
Theme III: What is the global prevalence and distribution
of TB stigma(s)? What explains any variation?
Policy makers, civil society, research organisations,
donors and activists are keen to knowwhere TB stigma
is most problematic so that they can channel scarce
resources. This theme focuses attention on the macro
level: how prevalent is TB stigma across the globe, and
how can valid global comparisons be made? (Table 4).
Figure 1 Potential impacts of stigma along a person’s TB care itinerary or trajectory (artist: R
Takahashi). TB¼ tuberculosis.
Table 2 What are the main drivers and facilitators of TB stigma(s)?
No
Research questions/
research topics
Foundational studies
references Level of measurement Study designs and methodology
1 How do the drivers of TB stigma
vary across contexts and
among types of stigma?
9,39,47 Individual: patients Qualitative research: ethnography
content reviewHealth system: HCWs/health
managers/CHWs
Community: leaders, key
spokespersons
Structural: policy-level triggers or
drivers
2 What are the structural drivers of
TB stigmas?
39,48 Societal systems and structures:
laws, policies, institutions,
rhetorics, architectures
Qualitative research:
ethnography, policy mapping
3 What are the drivers and
facilitators of compound
stigmas in key populations?
24,37,38,49–51 Individual: patients Ethnography, oral history, in-
depth interviewsHealth system: HCWs/health
managers/CHWs
Community: leaders, key
spokespersons
TB-affected populations who are
also marginalised for other
reasons
4 How are the drivers of MDR-TB
stigma and LTBI stigma
different from those of drug-
susceptible TB?
52 Individual: patients Qualitative research: ethnography
Health system: HCWs/health
managers/CHWs
Community: leaders, key
spokespersons
Key TB affected populations
TB¼ tuberculosis; HCW¼ health care worker; CHW¼ community health worker; MDR-TB¼multidrug-resistant TB; LTBI¼ latent tuberculous infection.
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Although normative influences upon stigma have been
mapped in broad strokes,16,17,19,45 multi-country
studies are few.12,13,32,74
Theme IV: What can be done to reduce the extent and
impact of TB stigma(s)?
Sommerland et al. report that the strength of the
evidence for interventions to reduce TB stigma is
limited.11 Well-designed trials to assess the effect of
changing societal, community, and individual atti-
tudes and behaviours to reduce stigma(s), as well as
interventions maximising resistance, resilience, and
strengthening or multiplying allies, are needed.59
Adapting effective interventions designed to address
other stigmas, such as leprosy, HIV or mental health,
may be an effective way forward.
We proposed to build on the stigma-reduction
framework of Heijnders and Van der Meij,74 and
chose the ‘onion’ as a familiar frame. As TB stigma
may operate at all levels from the individual to the
community, to health system level and to the wider
societal or structural levels (where policies operate),
our responses must also target particular social spaces
(Figure 2).
We recommend that all implementation science
specify which drivers, protective factors, actions or
behaviours are being targeted and which behavioural,
psychological or social theories underpin the inter-
vention. One way of gaining clarity is to insist on
determining if an intervention addresses the drivers of
TB stigma (fundamental intervention) or if it aims to
mitigate its consequences (symptomatic interven-
tion). While both types of interventions may be
needed, transparency on where in this chain of
‘driver-to-consequence’ the intervention takes place
could help us understand which interventions are
working, and why.
Practitioners should partner with researchers to
evaluate the media materials, curricula and counsel-
ling guides that are in use.75 Publishing negative
findings is as crucial as documenting success.4,11
Whether or not effective interventions will perform
equally well across settings is a research question that
must be answered empirically. Rood et al. and
Table 3 How consequential are TB stigmas? Where are TB stigma(s) impacts felt?
No
Research
questions/research topics
Foundational studies
references
Level of
measurement/population Study designs and methodology
1 Does TB stigma contribute to
poor care seeking or delay in
diagnosis?
59,49,60–64 Symptomatic persons with
undiagnosed TB
Interviews, life histories
2 Does stigma hamper quality
and completeness of contact
and outbreak investigations?
Does stigma reduce
willingness to disclose TB
disease to contacts?
60,63–65 HCWs, persons with TB Record review, key informant
interviews (patients and
HCWs)
3 Does stigma hamper TB
screening/diagnosis? Do
health workers hesitate to
ask TB patients about other
stigmatised identities,
diseases or behaviours?
59,33,66,67 Individual: patients
Health system: HCWs/health
managers/CHWs
Community: leaders, key
spokespersons
4 How do health workers
experience TB stigmas when
they provide TB services, does
it impact care?
59,33,68 HCWs Interviews, surveys, focus
groups
5 Does TB stigma hamper
treatment initiation?
54,69 PTLFU PTLFU surveys
6 Does TB stigma(s) worsen TB
outcomes via poor adherence
or loss to follow-up, death?
25,56 TB patients who drop out of
anti-tuberculosis treatment
Cohort studies, mortality
studies, verbal autopsy
studiesRelatives of those who have
died of suspected TB
7 Does stigma contribute to
catastrophic costs?
28 Affected households Macro- and micro-economic
analysis
8 Does stigma contribute to the
erosion of social capital and
social networks (social
impacts)?
70 Health system, community
leaders, key spokespeople
Social network studies
9 Does stigma hamper full
recovery and long-term self-
worth (mental health and
quality of life)?
24 Current and former TB patients Cohort study; medical record
review; surveys (patient, care
giver, family)
10 How consequential are stigmas
for public and individual
health and human rights?
13,59 Health system; legal and ethics
framework
Tracking systemic
discrimination, harassment,
isolation or breaking
confidentiality
TB¼ tuberculosis; HCW¼ health care worker; CHW¼ community health worker; PTLFU¼ pre-treatment loss to follow-up.
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Sommerland et al. argue that as TB stigma is often
compounded with other forms of discrimination,
combined stigma-reduction efforts are likely to be
synergistic (Table 5).11,13
Several behavioural-change theories could be used
to inform the design of stigma-reduction efforts in
public health. It remains true that some domains of
stigma (e.g., reified beliefs, attitudes and behaviours)
may be difficult to change, being sustained by
powerful interests, habit, culture, history and social
determinants.
CONCLUSION
Given the goal to eliminate suffering in people with
TB, and the urgent need to find and treat the 4 million
missing patients and strengthen the fight against
MDR-TB, there is an increasing mandate for valid
methods to estimate the burden of TB stigma(s).
One of the main outcomes of the above-mentioned
expert meeting in May 2016 was that, while the
world wants simple tools and checklists, complex
dilemmas remain to be resolved, including clarity on
what causes TB stigmas to emerge and thrive in
different contexts and populations. The challenge of
unpacking and measuring the intersectional aspects
of TB stigma, and the low likelihood of a ‘cure’ for
universal stigma being found, oblige diverse and
innovative approaches. While existing validated
scales are useful, new TB stigma scales need to be
developed and rigorously validated to fill the gaps.
Collectively, the meeting participants believed that
a powerful social force such as TB stigma is amenable
to appraisal and amelioration. We hope those
interested in reducing the suffering due to TB stigma
will use the proposed research agenda to join efforts
in achieving better measurement of TB stigma with
the ultimate goal of developing clear, focused and
effective interventions. People affected by TB have a
key role to play in the development and implemen-
tation of interventions to ensure that science is linked
to the reality of their experiences, and that proven
strategies for resistance, resilience and countering are
funded and fostered. While the research agenda
presented will require considerable resources and
planning, we are convinced that it is now time to
focus on the ‘how’, and not the ‘whether’, to measure
and reduce TB stigma.
Figure 2 An onion framework: spaces for intervention to
reduce stigma.50
Table 4 What is the global foot print of TB stigma(s)? What explains this variation?
No
Research questions/research
topics
Foundational studies
references
Level of
measurement/population Study designs and methodology
11 How do we optimise existing TB
stigma scales so that they can
be used cross-culturally?
10,15,29,25–28,33,36,71 Individual: patients Cross-sectional, comparative or
longitudinal surveys;
prospective observational
cohorts; case studies and in-
depth interviews
Community
Institutions
Laws and policies
12 How do we leverage existing
survey data?
1,12 Household surveys Secondary analysis of TB non-
disclosure for hypothesis
generation
13 How do we measure levels of
TB stigmas in key population
groups?
41–43,47 Individual: patients Based on qualitative work from
thematic area 1.2, conduct
surveys
Health workers
Community: leaders
Key populations: men,
miners, PLHIV, prisoners,
migrants
14 Is it possible to develop valid
‘mini scales’ and ‘rapid
assessments’ that capture TB
stigma?
55,72 Structural: policy use at
national and global level
for monitoring and
comparing over time
Embed in existing and
continuing surveys, e.g.,
prevalence surveys;
catastrophic cost surveys
15 What explains the variation in
stigmas across and within
countries? Are there
protective factors in some
settings?
4,13–15 Structural: legal frameworks Ecological analyses
Mapping of legal frameworks
using adapted legal
environment assessments
TB¼ tuberculosis; PLHIV¼ people living with human immunodeficiency virus.
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Table 5 What can be done to reduce TB stigma? (i.e., which interventions work?)
No
Research
questions/research topics
Foundational studies
references
Level of
measurement/population Study designs and methodology
16 Does increasing specific kinds of
knowledge reduce TB
stigma? What is protective?
13,76 Pragmatic trials, RCT, stepped
wedge designs
17 Which legal and policy reforms
reduce TB stigma?
77 Structural, e.g., progressive
legal interventions for non-
adherence; worker privacy
for DOT on the job
Repeat legal environment
assessment
Trend analyses
18 Which educational
interventions reduce TB
stigma?
32,68 Structural/Health System
Medical ethics education/
interpersonal skills/stigma
awareness training
Use of simulated patients with
students to assess language
used with communicating or
providing information
Assessments of teaching case
presentations about people
with TB —observe language
used
19 Which types of individual-level
psychosocial, nutritional,
economic supports foster
resilience to TB stigma?
11,36,31,78 Patient-level
Household-level
Assess the role of peer or health
worker support
20 How can infection control and
contact tracing behaviours be
modified to reduce stigma?
79 All levels/ultimately structural
and discourse levels
Pragmatic trials, RCT, stepped
wedge designs
21 How effective are shifts in
language and rhetoric to
reduce stigma?
80–85 Discourses, laws, media,
policies, recording and
reporting forms
Study using comprehensive
critical analysis and discourse
analysis of language used;
norms present or not present
Content review of print and
online media to determine
how TB is portrayed (e.g.,
epidemiology, patient names
or images)
22 What interventions are effective
with those who stigmatise?
32,76,83 Household/family/care givers
Policy makers
HCW
Pragmatic trials, RCT, stepped
wedge designs
23 How effective are interventions
adapted from other stigma
arenas (e.g., mental health,
leprosy, HIV)?
24,77,80,86–88 Pragmatic trials, RCT, stepped
wedge designs
24 What interventions are effective
against the consequences of
stigma?
Is stigma reduced by new
technology such as video
based-DOT/telemedicine and
SMS reminders that may
increase privacy and
confidentiality?
89,90 Organisational/health system:
HCW and managers/CHWs
Individual: patient and family
Adding new questions to health
facility and individual survey
questions; qualitative
methods looking at individual
responses
Matched case control study:
enrol patients in the
interventions not only
compare adherence and
health outcomes to non-
intervention groups, but ask
questions about extent of
stigma and shame
25 How well do effective stigma
reduction interventions
translate to other settings?
Diverse settings Multisite studies
26 Are some people more resilient
to stigma? How can allies be
cultivated to combat
discrimination?
12,91,92 Patient-level Case control
Participant observation
27 Which interventions are
effective against
intersectional stigmas?
37,59 Patient-level RCT
Pragmatic trials
28 Does improving TB service
delivery quality reduce
stigma? e.g., Is stigma
reduced by rapid diagnostics
or shorter regimens?
32 Facility-level Nested studies in evaluations of
non-stigma interventions
Pragmatic trials
TB¼ tuberculosis; RCT¼randomised controlled trial; HCW¼health care worker; HIV¼human immunodeficiency virus; DOT¼directly observed treatment; SMS¼
short message service; CHW¼ community health worker.
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R E´ S U M E´
La stigmatisation vis-a`-vis de la tuberculose (TB) rec¸oit
enfin, au niveau mondial, une attention bien me´rite´e, car
elle est cruciale pour identifier et traiter les 4 millions de
patients atteints de tuberculose (TB) qui sont
actuellement manque´s par les programmes nationaux
TB. La capacite´ a` mesurer et a` e´valuer le succe`s des
efforts de re´duction de la stigmatisation TB est
cependant limite´e par le besoin d’outils
supple´mentaires. Lors d’une re´union de mesure de la
stigmatisation TB qui a eu lieu a` La Haye en 2016, les
experts en stigmatisation ont discute´ et propose´ un
programme de recherche autour de quatre the`mes : 1)
Moteurs : quels sont les principaux moteurs et domaines
de la stigmatisation TB ? 2) Conse´quences : quelles sont
les conse´quences de la stigmatisation TB? Comment les
impacts ne´gatifs sont-ils surtout ressentis? 3) Fardeau :
quelle est la pre´valence mondiale et la distribution de la
stigmatisation TB? Comment s’expliquent les
variations? 4) Intervention : que peut-on faire pour
re´duire l’e´tendue et l’impact de la stigmatisation TB?
Chaque the`me a ensuite e´te´ subdivise´ en sujets de
recherche a` examiner pour faire avancer les choses. Ceci
inclut de clarifier les causes qui font e´merger et croıˆtre la
stigmatisation vis-a`-vis de la TB, la difficulte´ a` mesurer
la complexite´ de la stigmatisation et l’absence de
probabilite´ d’un reme`de universel. Ne´anmoins, ces
de´fis ne devraient pas entraver les investissements dans
la mesure et dans la re´duction de la stigmatisation
relative a` la TB. Nous pensons qu’il est temps pour la
communaute´ mondiale de se concentrer sur la manie`re
de mesurer et de re´duire la stigmatisation lie´e a` la TB et
non pas de se demander s’il faut le faire.
R E S UM E N
Dada la gran influencia que ejercen los estigmas
relacionados con la tuberculosis (TB) en la deteccio´n y
el tratamiento de los 4 millones de pacientes que se pasan
por alto en los programas nacionales contra la TB, se
otorga hoy a la estigmatizacio´n una atencio´n bien
justificada y tardı´a a escala mundial. Sin embargo, la
falta de instrumentos adecuados limita la capacidad de
medir y evaluar la eficacia de las iniciativas tendentes a
aminorar los estigmas asociados con la TB. En una
reunio´n celebrada en el 2016 en La Haya sobre la
medicio´n de la estigmatizacio´n por TB, expertos en el
tema analizaron y propusieron un programa de
investigacio´n en torno a los siguientes cuatro temas: 1)
los factores determinantes: ¿Cua´les son los principales
factores y las dimensiones de la estigmatizacio´n por TB?;
2) las consecuencias: ¿Que´ tanta repercusio´n tienen los
estigmas relacionados con la TB? ¿De que´ manera se
suelen percibir las repercusiones negativas?; 3) la carga:
¿Cua´l es la prevalencia mundial de estigmatizacio´n por
tuberculosis y co´mo se distribuye? ¿Co´mo se explican las
variaciones? 4): la intervencio´n: ¿Que´ puede hacerse a
fin de disminuir la magnitud y el impacto de la
estigmatizacio´n por TB? Luego, cada tema se
subdividio´ en los aspectos de investigacio´n que se
deben abordar con el fin de avanzar en el programa.
Estos aspectos incluyeron una mayor claridad sobre las
causas que hacen surgir y progresar los estigmas
relacionados con la TB, la dificultad de medir la
complejidad de los estigmas y la improbabilidad de un
‘remedio’ universal a la estigmatizacio´n. Sin embargo,
estas dificultades no deberı´an obstaculizar las
inversiones encaminadas a medir los estigmas
relacionados con la TB y a reducirlos. Los autores
consideran que llego´ el momento de centrar los esfuerzos
en decidir la forma como la comunidad mundial debe
medir y reducir la estigmatizacio´n por TB en lugar de
deliberar sobre la pertinencia de hacerlo.
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